| R&D Community of Practices (CoP) Meeting |
Meeting/ Workshop |
ACF, BARDA, CDC, CMS, FDA |
OD/OM, OD/OM/OALM |
The R&D Community of Practices allows agencies to work together to exchange problems and solutions for reporting requirements associated with R&D and to provide feedback to both OMB and NSF-NCSES on ways to improve the process of reporting. |
| Racial/Ethnic Variation of HPV Type Distribution in High-Grade Cervical Precancers and Invasive Cancers in the United States |
Research Initiative |
CDC |
NCI |
The National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating in pooled anlaysis of seven U.S. studies conducted between 1997-2015 to examine HPV genotype attribution for cervical precancer and cancer by race/ethnicity. |
| Radiation and Chemical Defense Working Group |
Committee, Work group, Advisory group, or Task Force |
BARDA, FDA, ASPR |
NIAID, NIAMS, NIEHS |
This group identifies scientific overlap between the chemical radiation defense missions ensures they are leveraged to advance the missions of both research areas. Goals are to understand areas of synergy in chemical and radiological insults, identify key pathways, foci of intervention, drug development. Team includes staff from across the NIH, FDA and ASPR. A scientific Zoom conference was held January 2022 and a Special Journal Issue resulting from the presentations and meeting report is nearly complete. A follow-on NOSI is in preparation to provide supplements to cross-pollinate the rad and chem research areas. |
| Radiation Biodosimetry Interagency Working Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIAID |
NIAID provides expertise on radiation biodosimetry topics and updates for the FDA / CDRH. |
| Radiation Biodosimetry Working Group |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIAID |
This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting the new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry. |
| Radiobiology Bioterrorism Research and Training Group (RABRAT) |
Committee, Work group, Advisory group, or Task Force |
ASPR, FDA |
NCI, NIAID |
This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism. |
| Rapid Acceleration of Diagnostics Tech Program |
Research Initiative |
ASPR, ASPR, BARDA, CDC, CMS, FDA |
NCI, NHLBI, NIAID, NIBIB, OD/DPCPSI/IMOD |
To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $651 million (in FY2021) to support the development of new SARS-CoV-2 virus testing technologies. The Rapid Acceleration of Diagnostics (RADx®) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. RADx Tech also established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public. |
| Rare Disease Day at NIH |
Meeting/ Workshop |
FDA |
NCATS, NCI, NHLBI, NIAAA, NINDS |
Rare Disease Day takes place worldwide, typically on or near the last day of February each year, to raise awareness among policymakers and the public about rare diseases and their impact on patients' lives. Each year, the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) Clinical Center sponsor Rare Disease Day at NIH as part of this global observance. Rare Disease Day at NIH aims to raise awareness about rare diseases, the people they affect, and NIH collaborations that address scientific challenges and advance research for new treatments. The goals of Rare Disease Day at NIH are to: demonstrate the NIH commitment to helping people with rare diseases through research; highlight NIH-supported rare diseases research and the development of diagnostics and treatments; initiate a mutually beneficial dialogue among the rare disease community; exchange the latest rare diseases information with stakeholders to advance research and therapeutic efforts; shine a spotlight on stories told by people living with a rare disease, their families, and their communities. |
| Rare Diseases Registry Program (RaDaR) |
Resource Development |
FDA |
NCATS |
NCATS launched the Rare Diseases Registry Program (RaDaR) website to provide the rare diseases community with easily accessible guidance on how to set up and maintain high-quality registries that are based on best practices and data standards. The goal is to enable rare diseases patient organizations to better promote and support patient-focused research and the collection of patient data that can be used in developing treatments for rare diseases. |
| Recognize, Assist, Include, Support and Engage (RAISE) Family Caregiving Advisory Council |
Committee, Work group, Advisory group, or Task Force |
ACL, ACF, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA |
NIA |
Federal and non-federal advisory council is charged with providing recommendations to the Secretary of Health and Human Services on effective models of both family caregiving and support to family caregivers, as well as improving coordination across federal government programs, as mandated by the Recognize, Assist, Include, Support, and Engage (RAISE) Family Caregivers Act of 2017. |